Advanced psychometric analysis and the Alzheimer’s Disease Neuroimaging Initiative: reports from the 2011 Friday Harbor conference

[1]  M. Glymour,et al.  Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease , 2012, Brain Imaging and Behavior.

[2]  A. Saykin,et al.  Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI , 2012, Brain Imaging and Behavior.

[3]  Alzheimer's Disease Neuroimaging Initiative,et al.  Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer’s disease , 2012, Brain Imaging and Behavior.

[4]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[5]  Meghan B. Mitchell,et al.  Confirmatory factor analysis of the ADNI neuropsychological battery , 2012, Brain Imaging and Behavior.

[6]  Meghan B. Mitchell,et al.  Cortical signatures of cognition and their relationship to Alzheimer’s disease , 2012, Brain Imaging and Behavior.

[7]  M. Glymour,et al.  Genetic architecture of resilience of executive functioning , 2012, Brain Imaging and Behavior.

[8]  L. Beckett,et al.  Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease , 2012, Brain Imaging and Behavior.

[9]  Philip S. Insel,et al.  A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment , 2012, Brain Imaging and Behavior.

[10]  E. Erosheva,et al.  CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer’s pathological cascade , 2012, Brain Imaging and Behavior.

[11]  G. Potter,et al.  The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI , 2012, Brain Imaging and Behavior.

[12]  E. Erosheva,et al.  CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer’s pathological cascade , 2012, Brain Imaging and Behavior.

[13]  Judy Pa,et al.  Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment , 2012, Brain Imaging and Behavior.

[14]  Michael W. Weiner,et al.  Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks , 2012, Brain Imaging and Behavior.

[15]  M. Fornage,et al.  Genome‐wide association studies of cerebral white matter lesion burden , 2011, Annals of neurology.

[16]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[17]  David A Wolk,et al.  Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  M. Fornage,et al.  Genome-Wide Association Studies of MRI-Defined Brain Infarcts: Meta-Analysis From the CHARGE Consortium , 2010, Stroke.

[19]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[20]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[21]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[22]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.